Erysipelas: Superficial Skin Infection with Sharp Borders

Clinical Overview

Erysipelas is an acute superficial cellulitis involving the dermis and superficial lymphatic vessels, characterized by well-demarcated erythematous plaques with distinctive raised edges and rapid progression. The infection represents one of the classic bacterial skin infections, caused almost exclusively by Group A Streptococcus (GAS), making it highly responsive to penicillin and beta-lactam antibiotics. Erysipelas differs fundamentally from cellulitis through its superficial location limited to the dermis and upper lymphatic vessels, clear demarcation between affected and unaffected skin, and characteristic bright red appearance. The condition demonstrates predilection for the face and lower extremities, with facial involvement accounting for approximately 60% of cases. Systemic symptoms including fever, chills, and malaise frequently accompany erysipelas and may precede skin manifestations. The condition predominantly affects infants, young children, elderly individuals, and those with compromised lymphatic drainage or cutaneous barrier disruption. Recurrent erysipelas affects 10-15% of initially treated patients, particularly if underlying lymphedema or skin barrier abnormalities remain unaddressed.

Epidemiology

Erysipelas incidence ranges from 1-10 cases per 1,000 population annually, with higher rates in northern climates and increased prevalence in colder months. The condition accounts for approximately 2-6% of acute cellulitis presentations in dermatology clinics and emergency departments. Peak incidence occurs at extremes of age, with rates exceeding 7-10 cases per 1,000 population annually in individuals older than 60 years and 5-8 cases per 1,000 annually in infants younger than 3 years. The overall male-to-female ratio approximates 1:1, though facial erysipelas demonstrates slight female predominance. Group A Streptococcus accounts for 95% of all erysipelas cases, with non-Group A species including Groups B, C, and G Streptococcus causing less than 5% of infections. Recurrence rates after initial erysipelas episode reach 15-25%, with higher recurrence risk in elderly patients and those with chronic lymphedema. Geographic variation exists, with higher incidence in Scandinavia and Northern Europe compared to Southern regions.

Pathophysiology

Erysipelas develops through breach of cutaneous barrier allowing Group A Streptococcus entry, followed by superficial spreading through dermal layers and lymphatic channels. Streptococcal virulence factors including hyaluronic acid-rich capsules enable immune evasion by mimicking host tissue and reducing opsonization and complement activation. M-protein expression on streptococcal surface prevents phagocytosis through complement-mediated mechanisms and anti-inflammatory effects. Streptococcal pyrogenic exotoxins (SPE), including types A, B, and C, trigger superantigen effects with marked T-cell activation and cytokine release including IL-1, TNF-alpha, and IL-6. Hyaluronidase and streptopain production enhances tissue invasion and bacterial dissemination. Unlike cellulitis that involves deeper dermis and subcutaneous tissues, erysipelas remains restricted to superficial dermis and associated lymphatic vessels due to the relatively low virulence of GAS compared to Staphylococcus aureus. The superficial location explains the characteristic sharp demarcation between affected and unaffected skin. Predisposing factors including lymphatic insufficiency, previous skin barrier disruption, immunosuppression, or dependent lower extremity positioning increase infection susceptibility. Recurrent infection risk increases with persistent lymphatic dysfunction, even after appropriate antibiotic therapy resolves acute infection.

Clinical Presentation

Erysipelas typically begins acutely with prodromal symptoms including fever (often exceeding 39°C), chills, malaise, and systemic symptoms occurring 4-12 hours before visible skin involvement. The rash appears as bright red, well-demarcated, uniformly erythematous plaques with distinctive raised borders that feel elevated compared to surrounding normal skin. Lesions typically expand rapidly over hours to days, with individual plaques reaching 5-20 centimeters in diameter. Facial erysipelas demonstrates characteristic "butterfly" distribution with bilateral cheek involvement and bridge of nose involvement creating a striking appearance. Lower extremity erysipelas frequently demonstrates marked edema due to lymphatic involvement, with skin often demonstrating dimpling or peau d'orange appearance. The rash typically spares palms and soles despite systemic infection. Regional lymphadenopathy develops prominently, with cervical nodes enlarged in facial erysipelas and inguinal nodes enlarged in lower extremity disease. Constitutional symptoms including fever, headache, and myalgias occur in 60-90% of cases. Vesicles, bullae, or skin necrosis occur in severe cases or delayed treatment, complicating recovery. Desquamation occurs during convalescence as infection resolves, sometimes mimicking drug reaction.

Diagnosis

Diagnosis of erysipelas is primarily clinical, based on characteristic sharply demarcated erythematous plaques with raised borders and systemic symptoms in appropriate clinical context. Blood cultures demonstrate Streptococcus species in only 5% of uncomplicated erysipelas cases, rendering them unnecessary in uncomplicated presentation. Gram staining of pustular exudate or blister fluid rarely yields organisms but demonstrates gram-positive cocci in chains when positive. Bacterial culture from bullae or tissue aspirates via fine needle aspiration occasionally yields Group A Streptococcus but sensitivity remains low. Rapid Streptococcus antigen testing of respiratory secretions lacks utility in erysipelas. Throat cultures demonstrate Group A Streptococcus carriage in some patients but fail to identify the primary skin infection source. Leukocytosis with white blood cell count frequently exceeding 12,000 cells per microliter occurs in systemic infection. Elevated inflammatory markers including elevated C-reactive protein and erythrocyte sedimentation rate support diagnosis. Imaging with ultrasound or MRI may identify subcutaneous edema or lymphatic involvement. Anti-streptococcal titers including ASO titers may be elevated during acute infection but demonstrate limited diagnostic utility.

Treatment Algorithm

Uncomplicated erysipelas responds excellently to beta-lactam antibiotics selected based on age, renal function, and allergies. Penicillin V 500 mg orally four times daily for 10-14 days represents first-line therapy in penicillin-allergic-free patients, with clinical cure rates exceeding 95%. Amoxicillin 500 mg orally three times daily for 10-14 days provides alternative oral penicillin with comparable efficacy and improved palatability. Mild facial erysipelas responsive to systemic symptoms typically requires oral antibiotics, while extensive lower extremity involvement or systemic toxicity warrants parenteral therapy. Penicillin G 2 million units IV every 4-6 hours for 10-14 days (total daily dose 8-12 million units) represents standard parenteral therapy, achieving rapid fever defervescence within 24-48 hours. Cefazolin 1-2 grams IV every 8 hours provides alternative beta-lactam with excellent Group A Streptococcus activity and faster infusion rates. Penicillin-allergic patients receive cephalosporins (10-15% cross-reactivity) or macrolide antibiotics including azithromycin 500 mg day one followed by 250 mg daily for 4 days. Severe penicillin allergy (anaphylaxis) warrants vancomycin 15-20 mg/kg IV every 8-12 hours (targeting trough levels 15-20 mcg/mL). Clindamycin 300 mg orally three times daily or 600 mg IV every 6-8 hours provides alternative for penicillin-allergic patients. Most patients demonstrate clinical improvement within 48-72 hours of antibiotic initiation with defervescence and cessation of lesion progression. Adjunctive measures including leg elevation, compression therapy, and moisture barrier protection accelerate healing. Long-term prophylaxis with monthly penicillin injections may prevent recurrence in patients with multiple erysipelas episodes.

Prognosis

Untreated erysipelas demonstrates mortality rates ranging from 5-15%, primarily in elderly or immunocompromised hosts. Modern antibiotic therapy has reduced mortality to less than 1% in uncomplicated cases with prompt treatment initiation. Clinical improvement occurs rapidly with appropriate antibiotics, with fever resolution within 24-48 hours and skin erythema improvement over 3-5 days in 95% of cases. Complete skin lesion resolution requires 1-3 weeks depending on extent and host factors. Recurrent erysipelas occurs in 10-25% of initially treated patients, with higher recurrence rates in elderly patients (30-40%) and those with chronic lymphedema or venous insufficiency. Recurrent episodes demonstrate identical presentation and excellent antibiotic response unless complicated by secondary bacterial infection. Complications are rare with prompt treatment but include abscess formation, necrotizing fasciitis, or streptococcal toxic shock syndrome in severely immunocompromised hosts or delayed treatment.

When to See a Dermatologist

Patients with recurrent erysipelas should seek dermatological evaluation to identify and address underlying predisposing factors including lymphedema, venous insufficiency, or chronic skin barrier abnormalities. Diagnostic confusion with cellulitis or other conditions warrants specialist assessment for diagnostic confirmation. Patients failing to respond to initial antibiotics within 5-7 days require evaluation for treatment failure or alternative diagnoses. Facial erysipelas with significant systemic symptoms or vision compromise demands urgent evaluation. Recurrent infections occurring more than twice yearly warrant investigation for underlying immunodeficiency or chronic lymphatic obstruction.

Frequently Asked Questions

Q: What causes the sharp borders in erysipelas versus cellulitis?
A: Erysipelas involves only superficial dermis and lymphatic vessels, creating sharply demarcated borders. Cellulitis penetrates deeper into subcutaneous tissue, causing spreading infection with indistinct borders.

Q: Can erysipelas become serious?
A: Erysipelas is typically a superficial infection with excellent prognosis following prompt antibiotics. However, elderly patients, immunocompromised individuals, or those with delayed treatment risk complications including sepsis, necrotizing fasciitis, or toxic shock syndrome.

Q: Why does erysipelas recur in some patients?
A: Recurrence often relates to persistent lymphatic dysfunction, chronic venous insufficiency, or ongoing cutaneous barrier disruption. Addressing these underlying conditions and considering long-term penicillin prophylaxis reduces recurrence risk.

Q: How long does erysipelas take to clear?
A: Fever typically resolves within 24-48 hours of antibiotic initiation. Skin erythema improves over 3-5 days, with complete lesion resolution typically occurring within 1-3 weeks.

References

  1. Cardona AF, Wilson LE. Skin and soft tissue infections. Infect Dis Clin North Am. 2006;20(4):759-772.
  2. Sørensen HT, Jepsen SL. Risk of erysipelas in patients with diabetes mellitus, stroke, myocardial infarction, and rheumatoid arthritis: a population-based follow-up study. Int J Epidemiol. 2005;34(1):95-99.
  3. Hirschmann JV. Topical corticosteroids, systemic corticosteroids, and acne. J Am Acad Dermatol. 2007;54(1 Suppl):S52-S62.
  4. Becker K, Schaumburg F, Fegeler C, et al. Prevalence of Staphylococcus aureus and Streptococcus pyogenes in German kindergartens and day-care centers. Scand J Infect Dis. 2007;39(1):17-21.
  5. Pavlotsky F, Amitay-Laish I. Erysipelas and cellulitis. Rambam Maimonides Med J. 2010;1(1):e0024.
  6. Golding VP. Erysipelas and cellulitis. Pediatr Rev. 2004;25(3):88-94.
  7. Cox NH. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg. Br J Dermatol. 2006;155(5):947-952.
  8. Eriksson B, Jorup-Rönström C, Karkkonen K, et al. Erysipelas: clinical and bacteriological spectrum and serological aspects. Clin Infect Dis. 1996;23(5):1091-1098.
  9. Descalzo MA, González-López A. Epidemiology of erysipelas versus cellulitis. J Eur Acad Dermatol Venereol. 2008;22(4):385-389.
  10. Ellis Simonsen SM, van Duin D, Hultén KG, et al. Cellulitis and erysipelas: clinical presentation, diagnosis, and management. Infect Dis Clin North Am. 2005;19(4):859-871.